The goal of Personalized Medicine is to implement advances in biomarker pharmacology, molecular diagnostics and genomics to improve public health. For the full benefits of this science to be realized, it is critical that scientific advancs made in experimental settings and on a small scale be extended to community practice and that a business case can be made to support such dissemination. It is important that key innovations be extended beyond individual hospital settings to large health care systems, especially those that include underserved populations. Many scientific advances bypass underserved populations, and as a result inequalities of care and cost inefficiencies result. In 2011, the Indiana Institute for Personalized Medicine (IPM) was created to serve as an academic home for basic and clinical researchers committed to research in personalized medicine. A specific goal of the IPM is to move this science towards clinical practice. To that end, the purpose of this proposal is to pilot a genomic platform in a large safety-net health care system, and to measure the economic costs and clinical outcomes of doing so. Eskenazi Health handles over 1.2 million outpatient visits per year and > 15,000 admissions annually, with a payer mix that include 45% uninsured, 26% Medicaid and 18% Medicare patients. In this proposal, the IPM will partner with Eskenazi Health and the Regenstrief Institute to recruit a new Eskenazi cohort of genotyped patients. A multidisciplinary group of clinicians and information scientists will pilot an innovatie approach to the implementation of pharmacogenomic science. The Regenstrief Institute has a proven track record of innovation in medical informatics, and has created an ideal environment in which to assess real clinical outcomes.
The specific aims of this proposal will be: 1) To test the hypothesis that a CLIA certified genotyping test targeted at 24 widely used drugs is associated with significant reductions in hospital and outpatient economic costs incurred over 1 year; and 2) To test whether such pharmacogenetic testing is associated with significant improvements in clinical outcomes over 1 year. Patients will be randomized either to an intervention arm, involving pharmacogenotyping, insertion of results in the medical record and dissemination of relevant results and decision algorithms to providers (n=2000 patients), or to usual care (n=4000 patients). This trial will be implemented in Eskenazi primary care clinics and 6 specialty clinics. Economic costs and clinical outcomes including clinic visits, hospital admissions, length of stay, adverse drug reactions, morbidity and mortality, will be followed prospectively and compared between the two groups. To sustain this effort, we will extend access to this testing to IU Health, and the affiliated NCI Simon Cancer Center and Riley Hospital for Children. Data from this study will allow for the first time the development of an objective business case for pharmacogenomic personalization based on real world costs and outcomes.

Public Health Relevance

The implementation of personalized medicine using genomic approaches to clinical care is currently compromised by lack of data on health care cost and meaningful patient outcomes. Collecting these data in large health care systems is key to the widespread clinical implementation of genomic science. In order to provide an evidence base to expand pharmacogenomic science beyond an academic setting, we propose a randomized, prospective pilot trial of broad pharmacogenomics interventions in which economic costs and clinical outcomes can be measured in an inner city system that serves the underserved.

Agency
National Institute of Health (NIH)
Institute
National Human Genome Research Institute (NHGRI)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01HG007762-04S2
Application #
9688326
Study Section
Special Emphasis Panel (ZHG1)
Program Officer
Madden, Ebony B
Project Start
2014-09-05
Project End
2019-04-30
Budget Start
2018-05-09
Budget End
2019-04-30
Support Year
4
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Indiana University-Purdue University at Indianapolis
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
603007902
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Levy, Kenneth D; Blake, Kathryn; Fletcher-Hoppe, Colette et al. (2018) Opportunities to implement a sustainable genomic medicine program: lessons learned from the IGNITE Network. Genet Med :
Zebrowski, Alexis M; Ellis, Darcy E; Barg, Frances K et al. (2018) Qualitative study of system-level factors related to genomic implementation. Genet Med :
Empey, Philip E; Stevenson, James M; Tuteja, Sony et al. (2018) Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy. Clin Pharmacol Ther 104:664-674
Cavallari, Larisa H; Lee, Craig R; Beitelshees, Amber L et al. (2018) Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. JACC Cardiovasc Interv 11:181-191
Fulton, Cathy R; Swart, Marelize; De Luca, Thomas et al. (2018) Pharmacogenetics and Practice: Tailoring Prescribing for Safety and Effectiveness. J Nurse Pract 14:697-704.e1
Vassy, Jason L; Stone, Annjanette; Callaghan, John T et al. (2018) Pharmacogenetic testing in the Veterans Health Administration (VHA): policy recommendations from the VHA Clinical Pharmacogenetics Subcommittee. Genet Med :
Sperber, Nina R; Carpenter, Janet S; Cavallari, Larisa H et al. (2017) Challenges and strategies for implementing genomic services in diverse settings: experiences from the Implementing GeNomics In pracTicE (IGNITE) network. BMC Med Genomics 10:35
Pierson, Rebecca C; Gufford, Brandon T; Desta, Zeruesenay et al. (2017) Clinical and educational impact of pharmacogenomics testing: a case series from the INGENIOUS trial. Pharmacogenomics 18:835-841
Cavallari, L H; Beitelshees, A L; Blake, K V et al. (2017) The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting. Clin Transl Sci 10:143-146
Ipe, J; Swart, M; Burgess, K S et al. (2017) High-Throughput Assays to Assess the Functional Impact of Genetic Variants: A Road Towards Genomic-Driven Medicine. Clin Transl Sci 10:67-77

Showing the most recent 10 out of 21 publications